{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04648280",
            "orgStudyIdInfo": {
                "id": "SHIELD (Penta22)"
            },
            "organization": {
                "fullName": "PENTA Foundation",
                "class": "NETWORK"
            },
            "briefTitle": "Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance",
            "officialTitle": "A Multicenter, Open-label, Single-arm Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Fostemsavir in Combination With Optimized Background Therapy (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their Current Combination Antiretroviral Therapy (cART) and Have Dual- or Triple-class Antiretroviral (ARV) Resistance",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "safety-and-pharmacokinetics-evaluation-of-fostemsavir-obt-in-hiv-infected-children-and-adolescents-who-are-failing-their-cart-and-have-dual-or-triple-class-antiretroviral-resistance"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2022-06-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-10",
            "studyFirstSubmitQcDate": "2020-11-23",
            "studyFirstPostDateStruct": {
                "date": "2020-12-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-03",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "PENTA Foundation",
                "class": "NETWORK"
            },
            "collaborators": [
                {
                    "name": "ViiV Healthcare",
                    "class": "INDUSTRY"
                },
                {
                    "name": "PHPT Foundation",
                    "class": "UNKNOWN"
                },
                {
                    "name": "Hospital Universitario 12 de Octubre",
                    "class": "OTHER"
                },
                {
                    "name": "Cromsource",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In the SHIELD study, the study sponsor seeks to assess safety, PK and antiviral activity for children and adolescents with dual or triple class resistance. It will also assess the acceptability and swallowability of formulation among the pediatric population. The dose selection of FTR for children and adolescents \u226520kg utilized a population pharmacokinetic (POP PK) model-based approach to achieve similar adult TMR exposures following FTR 600mg BID administration with combination therapy that was demonstrated to be safe and effective in the FTR Phase 3 BRIGHTE study in HTE patients."
        },
        "conditionsModule": {
            "conditions": [
                "HIV Infections With Multi Drug Resistant Virus"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Fostemsavir",
                    "type": "EXPERIMENTAL",
                    "description": "Fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance",
                    "interventionNames": [
                        "Drug: Fostemsavir"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Fostemsavir",
                    "description": "fostemsavir in combination with optimized background therapy (OBT) in HIV-1 infected children and adolescents who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class ARV resistance",
                    "armGroupLabels": [
                        "Fostemsavir"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Occurrence of the following events through Week 24",
                    "timeFrame": "24 weeks"
                },
                {
                    "measure": "AUC(0-tau)",
                    "timeFrame": "at week 1, 4, 12, 24, 48"
                },
                {
                    "measure": "Cmax",
                    "timeFrame": "at week 1, 4, 12, 24, 48"
                },
                {
                    "measure": "Ctau of temsavir across weight bands",
                    "timeFrame": "at week 1, 4, 12, 24, 48"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Proportion of patients with HIV-1 RNA <50 copies/mL",
                    "description": "To evaluate the antiviral activity of fostemsavir + OBT",
                    "timeFrame": "at 24 weeks and 48 weeks"
                },
                {
                    "measure": "Change in log10 HIV-1 RNA from baseline",
                    "timeFrame": "at 24 weeks and 48 weeks"
                },
                {
                    "measure": "Occurrence of: AEs, treatment-related AEs, AEs of Grade 3 or higher, serious AEs, and AEs leading to premature study treatment discontinuation.",
                    "timeFrame": "at Week 48 and at the end of Study"
                },
                {
                    "measure": "Occurrence of WHO 3 or 4 defining events, or death",
                    "timeFrame": "up to 156 weeks"
                },
                {
                    "measure": "efficacy of fostemsavir plus OBT",
                    "description": "changes from baseline in CD4+ T cell counts and the percentage of CD4 + T-cells",
                    "timeFrame": "up to 156 weeks"
                },
                {
                    "measure": "Emergence of genotypic or phenotypic resistance to Temsavir and components of OBT",
                    "timeFrame": "up to 156 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male and female HIV-1 infected paediatric participants from 6 years old and weighing at least 20 kg to less than 18 years of age.\n* Antiretroviral-experienced with documented historical or baseline resistance to one or more agents in at least two classes. All resistance has to be properly documented.\n* Failing current antiretroviral regimen with a confirmed plasma HIV-1 RNA \u2265 1000 c/mL (first value from Investigator within 6 months of screening visit, with the second value obtained from Screening labs, without a decline greater than 1 log10, and no value \\<1000 in between).\n* Documented resistance to at least one component of the current failing regimen per screening resistance testing.\n* Must have at least 1 fully active and available agent in 2 or more ARV classes, based on current and/or documented historical resistance testing, taking into account tolerability, and other safety concerns. At least two fully active agents must be a part of the initial OBT to be paired with FTR.\n* Girls who have reached menarche must have a negative pregnancy test at screening, not be breastfeeding, and be willing to adhere to effective methods of contraception if sexually active. All participants (male or female) have to agree with recommendations for effective contraception.\n\nExclusion Criteria:\n\nMedical History and Concurrent Diseases:\n\n* Unable to comply with dosing requirements (to swallow solid pharmaceutical form of the investigational medicinal product)\n* Unable to comply with study visits\n* Presence of a malabsorption syndrome or other gastrointestinal dysfunction which might interfere with drug absorption or render the participant unable to take oral medication.\n* Any clinical condition (including but not limited to recreational drug use) or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study\n* Pregnancy and breastfeeding\n\nPhysical and Laboratory Test Findings:\n\n* Chronic untreated Hepatitis B virus (HBV) (however, participants with chronic treated HBV or spontaneously remitted HBV are eligible)\n* HIV-2 infection\n* Alanine aminotransferase (ALT) \u22655 times the upper limit of normal (ULN), OR ALT \u22653xULN and bilirubin \u22651.5xULN (with\\>35% direct bilirubin)\n* History of unstable liver disease, decompensated cirrhosis, or known biliary disorder\n* History of congestive heart failure, or congenital/acquired prolonged QT syndrome/other cardiac diseases predisposing to prolonged QTc\n* Hemoglobin \\< 8.0 g/dL\n* Platelets \\< 50,000 cells/mm3\n* Confirmed QTcF value \\> 450 msec, regardless of sex, at Screening or Day 1\n* Current (defined as taking the medication within 14 days of Day 1) or anticipated treatment with medication considered prohibited or restricted as per Appendix II. Certain medication will be carefully evaluated as acceptable, see Appendix II.\n* Participation in an experimental drug and/or HIV-1 vaccine trial(s) within the previous 30 days\n* Child in governmental care, e.g. child is a ward of the state. Note: This criterion does not apply if the child is officially adopted by a family/guardian.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "6 Years",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pablo Rojo",
                    "role": "CONTACT",
                    "phone": "7169822",
                    "phoneExt": "0039049",
                    "email": "pablorojoconejo@netscape.net"
                },
                {
                    "name": "Alessandra Nardone",
                    "role": "CONTACT",
                    "phone": "7169822",
                    "phoneExt": "0039049",
                    "email": "alessandra.nardone@pentafoundation.org"
                }
            ],
            "locations": [
                {
                    "facility": "The George Washington University, Children's National Health System",
                    "status": "RECRUITING",
                    "city": "Washington",
                    "state": "District of Columbia",
                    "zip": "20010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Natella Rakhmanina",
                            "role": "CONTACT",
                            "email": "NRakhman@childrensnational.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.89511,
                        "lon": -77.03637
                    }
                },
                {
                    "facility": "Children's Healthcare of Atlanta",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Andres Camacho-Gonzalez",
                            "role": "CONTACT",
                            "email": "acamac2@emory.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Hospital General Mexico",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Mexico City",
                    "country": "Mexico",
                    "contacts": [
                        {
                            "name": "Noris Pavia Ruz",
                            "role": "CONTACT",
                            "email": "norpavruz@yahoo.com.mx"
                        }
                    ],
                    "geoPoint": {
                        "lat": 19.42847,
                        "lon": -99.12766
                    }
                },
                {
                    "facility": "FAM-CRU",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Cape Town",
                    "country": "South Africa",
                    "geoPoint": {
                        "lat": -33.92584,
                        "lon": 18.42322
                    }
                },
                {
                    "facility": "King Edward VIII Hospital",
                    "status": "RECRUITING",
                    "city": "Durban",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Moherndran Archary",
                            "role": "CONTACT",
                            "email": "archary@ukzn.ac.za"
                        }
                    ],
                    "geoPoint": {
                        "lat": -29.8579,
                        "lon": 31.0292
                    }
                },
                {
                    "facility": "Rahima Moosa Mother and Child Hospital",
                    "status": "RECRUITING",
                    "city": "Johannesburg",
                    "zip": "2112",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Renate Strehlau",
                            "role": "CONTACT",
                            "email": "Renate.Strehlau@wits.ac.za"
                        }
                    ],
                    "geoPoint": {
                        "lat": -26.20227,
                        "lon": 28.04363
                    }
                },
                {
                    "facility": "Wits Reproductive Health and HIV Institutel",
                    "status": "RECRUITING",
                    "city": "Johannesburg",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Feezah Patel",
                            "role": "CONTACT",
                            "email": "faeezah.patel@wits.ac.za"
                        }
                    ],
                    "geoPoint": {
                        "lat": -26.20227,
                        "lon": 28.04363
                    }
                },
                {
                    "facility": "PHRU",
                    "status": "RECRUITING",
                    "city": "Soweto",
                    "country": "South Africa",
                    "contacts": [
                        {
                            "name": "Avy Violari",
                            "role": "CONTACT",
                            "email": "violari@mweb.co.za"
                        }
                    ],
                    "geoPoint": {
                        "lat": -26.26781,
                        "lon": 27.85849
                    }
                },
                {
                    "facility": "Hospital 12 de Octubre",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Madrid",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015658",
                    "term": "HIV Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000015229",
                    "term": "Sexually Transmitted Diseases, Viral"
                },
                {
                    "id": "D000012749",
                    "term": "Sexually Transmitted Diseases"
                },
                {
                    "id": "D000016180",
                    "term": "Lentivirus Infections"
                },
                {
                    "id": "D000012192",
                    "term": "Retroviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "asFound": "HIV Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15558",
                    "name": "Sexually Transmitted Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17933",
                    "name": "Sexually Transmitted Diseases, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M18640",
                    "name": "Lentivirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15026",
                    "name": "Retroviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000576364",
                    "term": "Fostemsavir"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                },
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000023581",
                    "term": "HIV Fusion Inhibitors"
                },
                {
                    "id": "D000065147",
                    "term": "Viral Fusion Protein Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M340653",
                    "name": "Fostemsavir",
                    "asFound": "Diprospan",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}